taiwan expo usa

Chien-Jen Chen, Sc.D., Ph.D.

Genomics Research Center, Academia Sinica, Taiwan

Presentation Introduction

Biomedicine was incorporated into the 5+2 Industry Innovation Plan in 2017, and precision health became one of the Six Core Strategic Industries in 2020 in Taiwan. The strategy to actively support and strengthen biomedical industry resulted in a revenue of over US$19 billion in 2019 alone. The health care system of Taiwan was ranked as the second best (next to South Korea) by CEOWORD Magazine in 2021, and Taiwan’s health care index was ranked as the best by NUMBEO in 2022.

Precision epidemic prevention system was launched in early 2020, which has successfully contained COVID-19 epidemic and sustained economic growth in Taiwan. To cope with the widespread Omicron variants in 2022, increased coverage of vaccine boosters, rapid diagnostics and antivirals through telemedicine has kept low rates of confirmed COVID-19 deaths and estimated excess deaths from all causes during the pandemic in Taiwan.

The integration of Taiwan’s excellent biomedical R&D, digital care and smart medicine, national health insurance system, multi-centered clinical trials consortium, national biobanks, Medi-Cloud and big data in healthcare, information and communication infrastructure, ambient intelligence, and niche products is expected to allow the country to become a major hub for the precision health and digital medicine in the Asia-Pacific region.

Speaker Introduction

Education

B.Sc., Department of Zoology, College of Science, National Taiwan University M.P.H., Graduate Institute of Public Health, College of Medicine, National Taiwan University Sc.D., Department of Epidemiology, School of Hygiene and Public Health, Johns Hopkins University

Professional Experience

Professor, National Taiwan University (NTU) College of Public Health (1986-2015)

Research Fellow, Institute of Biomedical Sciences, Academia Sinica (1988-1994)

Director, Graduate Institute of Public Health, (NTU) College of Public Health (1993-1994)

Director, Graduate Institute of Epidemiology, (NTU) College of Public Health (1994-1997)

Director General, Division of Life Sciences, National Science Council (1997-1999)

Dean, College of Public Health, National Taiwan University (1999-2002)

Deputy Minister, National Science Council, Executive Yuan (2002-2003)

Minister, Department of Health, Executive Yuan (2003-2005)

Minister, National Science Council, Executive Yuan, Republic of China (2006-2008)

Distinguished Research Fellow, Genomic Research Center, Academia Sinica (2006- 2015)

Vice President, Academia Sinica (2011- 2015)

Vice President, the Republic of China (Taiwan) (2016-2020)

Specialties Epidemiology, Human Genetics, Public Health, Preventive Medicine

Awards and Honors

Outstanding Research Award (1986-1996), Outstanding Research Fellow Award (2003), National Science Council

Fogarty International Research Fellowship, US National Institute of Health (1989)

Overseas Fellow(1989), Fellow(1993), American College of Epidemiology, USA Medical Research Award, Ching-Hsing Medical Foundation (1990) Medical Research Award, United Medical Foundation (1992)

Outstanding Teaching Award (1992), Academic Award (1997), National Chair Professor (1999-2002), Ministry of Education

Outstanding Scholar, Foundation for Outstanding Scholarship (1995-1999) Health Medal (Second Rank) (1996), Health Medal (First Rank) (2005), Department of Health

Academician, Academia Sinica, Taiwan (1998)

Outstanding Anti-Cancer Research Award, Taiwan Cancer Foundation (1999)

Dr. T.-M. Tu Memorial Lectureship, Dr. T.-M. Tu Scholarship Foundation (2002) Achievement Medal (First Rank), Executive Yuan, ROC (2005)

Presidential Science Prize, ROC (2005)

Member, Academy of Sciences for the World (2005)

Honorary Member, Mongolian Academy of Sciences (2007)

Dr. D. V. Datta Memorial Orator, Indian National Association for Study of the Liver (2008)

Cutter Lecturer on Preventive Medicine, Harvard University, USA (2008)

Officier dans l’Ordre des Palmes Academiques, Ministry of Education, France (2009) Science and Engineering Achievement Award, Taiwanese-American Foundation, USA (2009)

Member, Delta Omega Honorary Society in Public Health, Johns Hopkins University, USA (2010)

Outstanding Academic Award, Wang Ming-Ning Memorial Foundation, Taiwan (2010)

Vikit Viranuvatti Lecturer, Gastroenterological Association of Thailand (2011)

Science Profession Medal (First Prize), National Science Council, ROC (2012)

Knowledge for the World Award, Johns Hopkins University, USA (2012)

Outstanding Contribution in Science and Technology Award, Executive Yuan, ROC (2013)

Honorary Degree of Doctor of Philosophy, China Medical University, Taiwan (2014)

Prof. Juei-Low Sung Award, Asia-Pacific Primary Liver Cancer Expert Association (2014)

Distinguished Service Medal, Academia Sinica (2016)

Foreign Associate, National Academy of Sciences, USA (2017)

Honorary Doctor of Philosophy, Kaohsiung Medical University, Taiwan (2020)

Honorary Doctor of Science, National Sun Yet-Sen University, Taiwan (2020)

Order of Dr. Sun Yat-sen with Grand Cordon, Office of the President, Taiwan (2020)

Academician, Pontifical Academy of Sciences, Vatican (2021)

Chi-Huey Wong

Scripps Family Chair Professor of Chemistry,The Scripps Research Institute, La Jolla, California 92037, USA and Distinguished Professor, Genomics Research Center, Academia Sinica, Taiwan

Presentation Introduction

The global healthcare spending continues to grow and is expected to reach $15 trillion dollars in 2030, and the fastest growing area is for early diagnosis and disease prevention accounting for 30% of the projected spending. This trend indicates a shift from disease treatment to prevention. To make the prevention care more accurate and cost-effective, the technologies commonly used in the information and communication industry should be contributed to product development. Within this context, this lecture will present our recent development of broadly protective vaccines against SARS-CoV-2 and its variants.

Since the outbreak of SARS-CoV-2 in 2019, the virus continues to spread and mutate with more than ten million spike protein sequences reported, and the vaccines used to date begin to fade their protection against the emerging variants, though they are highly protective against serious conditions. To develop a more effective and broadly protective vaccine, our approach is to remove the sugar coat from the spike protein to better expose the highly conserved epitopes and use the sugar-free spike protein or its mRNA for vaccine design. Both vaccines in animal models were shown to elicit more enhanced and broadly protective responses against the variants of concern, including the delta variant and all omicron subvariants as compared to the current vac cines.

Speaker Introduction

Professor Wong received his B.S. (1970) and M.S. (1977) degrees in biochemical sciences (with KT Wang) from National Taiwan University, and Ph.D. (1982) in Chemistry (with George M. Wh itesides) from MIT. After one year of postdoctoral research at Harvard University (with George M. Whitesides), he became a faculty member of the chemistry department at Texas A&M University (1983) where he was promoted to full professor in 1987. He then moved to The Scripps Re search Institute in 1989 as Professor and Ernest W. Hahn Chair in Chemistry, and from 2006 to 2016, he served as President of Academia Sinica in Taiwan. He is currently the Scripps Family Chair Professor of Chemistry at The Scripps Research Institute and holds a joint appointment as Distinguished Professor at Genomics Research Center, Academia Sinica.

Professor Wong received many honors for recognition of his accomplishments. Some represen tative honors include: Presidential Young Investigator Award in Chemistry, USA (1986), Roy Whistler Award of the International Carbohydrate Organization (1994), ACS Harrison Howe Award in Chemistry (1998), ACS Claude S. Hudson Award in Carbohydrate Chemistry (1999), International Enzyme Engineering Award (1999), Presidential Green Chemistry Challenge Award, USA (2000), ACS Award for Creative Work in Synthetic Organic Chemistry (2005), ACS Arthur C. Cope Medal (2012), The Wolf Prize in Chemistry, Israel (2014), The Royal Society of Chemistry Robert Robinson Award, UK (2015), The Robert A. Welch Award in Chemistry, USA (2021) and The American Institute of Chemists Chemical Pioneer Award (2022). He is an elected member of Academia Sinica (1994), the American Academy of Arts and Sciences (1996), the US National Academy of Sciences (2002), the World Academy of Sciences (2007), the European Molecular Organization (2010) and the US National Academy of Inventors, USA (2014).

In addition, he served as editorial advisor for several journals in chemistry and chemical biology, as scientific advisor for many organizations including the Max-Planck Institute (2000-2008) and RIKEN (2010-16), as Chairman of the Executive Board of Editors of the Tetrahedron Publications (2006-2008), Head of the Frontier Research Program on Glycotechnology at RIKEN in Japan (1991-1999), Board Member of the US National Research Council on Chemical Sciences and Technology (2000-2003), the Chief Science Advisor for Taiwan Government (2006-2015) and President of Institute for Biotechnology and Medicine Industry, Taiwan (IBMI) (2019-).

His research interests are in the field of chemical biology and synthetic chemistry, with current focus on the development of new methods and tools for the synthesis and study of complex carbohydrates and glycoproteins, elucidation of carbohydrate-mediated recognition in disease progression and immune response, and development of universal vaccines against cancer and viral pathogens such as influenza and SARS-CoV-2. He trained over 500 graduate students and postdoctoral fellows, published over 750 papers and 120 patents, and is a highly cited scientist with an h-index of 150.

Dr. Matthew Y.C. Lin

Vice President, AHMC Healthcare

Presentation Introduction

The pandemic has had a profound impact on Health care system, including, financial and operational challenges, workforce shortages, behavioral health needs, digital health access, and care delivery transformation. By 2023, healthcare markets will be under pressure to find revenue and government will be entering a period of significant disruption.

According to the President’s Budget Plan released this March which will be effective from fiscal year 2023 through 2032. There’s 26.8% increase spending from the 2021 for expanded health coverage and services, such as mental health needs, healthcare access, health research and innovation, and etc.

In this presentation, I would like to share: The major innovations in 2022 that could transform healthcare, such as next generation of mRNA vaccinology, AI for early sepsis detection…,etc. The biggest technology trends in 2022, such as remote healthcare and telemedicine, personal ized medicine and genomics…, etc. We would also like to share the future of healthcare and the opportunity for Taiwan.

Speaker Introduction

Professional Experience

Senior advisor for HHS (2018 &2019)

Advisory council in the National advisory Council for minority Health and Health disparity in National institute for minority Health, NIH (2019-2020)

Assistant Dean, California Northstate University College of Medicine (2014-2017)

President, AHMC International Cancer Center (2011-2017)

Chairman , AHMC CentralHealth Plan, LLC (2010-2016)

Vice-Chairman, AHMC Healthcare Inc. Board of Directors (since 2004)

*AHMC Healthcare Inc. is the owner/operator of 10 hospitals in Southern California. We have roughly 9000 employees and thousands of contracted physician medical staff.

Associate Professor of Orthopedic Surgery, Western University of &Health Science (1996 -2017)

Medical & Non-Medical Associations (Partial List)

Mayor, Vice-Mayor and City Councilman, City of San Marino, California (2001-2009)

*Served 3 term as Mayor

Board of Directors, San Francisco Theological Seminary (2005-2009)

Member, Board of Trustees, San Marino Community Church Foundation (2004-2008)

Member, Board of Directors, Taiwan Center, California (2005-2007)

Member, Board of Directors, Pasadena Symphony Association (1989-1990)

Member, Board of Trustees, San Marino School Foundation (1990-1991)

Member, Board of Directors, United Way (1989-1990)

Member, California Institute of Technology (Caltech) Associates (2008-2016)

Member, Board of Directors, Garfield Medical Center (1990-1994)

Chief of Staff, Garfield Medical Center (1987-1990)

President, Los Angeles County Medical Association, San Gabriel Valley District (1990)

Field Partner, Doctors Without Borders

Member, American Medical Association

Member, American Academy of Orthopedic Surgery

Member, American Board of Orthopedic Surgery

Member, California Medical Association

Member, California Orthopedic Association

Member, Western Orthopedic Association

Member, Los Angeles County Medical Association

Member, Johns Hopkins University Association

Member, Taiwan Medical Society

Awards and Honors (Partial List)

Leadership Award for Public Service, Los Angeles County Medical Association (2012)

Heart of the Community Award, YMCA of West San Gabriel Valley (2012)

Leadership in Governance Award, California Hospital Association (2011)

Corporate Citizen of the Year, East Los Angeles College Foundation (2010)

Outstanding Alumni Award, Taipei Medical University (2008)

Platinum Public Service and Role Model Award, Western University of Health Services (2005-2006)

Community Leadership Award, West San Gabriel Valley Boys and Girls Club (2005) Humanitarian Award, U.S. Representative Judy Chu (2005)

25 Years of Dedication and Outstanding Services, Garfield Medical Center (2004)

Outstanding Leadership and Distinguished Contribution Award, Taiwanese Engineers and Scientists Society of America (2003)

Citizen of the Year, San Marino Tribune (2002)

Outstanding Role Model, Western University of Health Services (1999)

Hall of Fame Inductee, West San Gabriel Valley Boys and Girls Club (1997)

Outstanding Support and Concern for Youth, West San Gabriel Valley Boys and Girls Club (1995)

Education EDUCATION: Taipei Medical University, Taipei, Taiwan, Republic of China

Graduated June 20, 1971

INTERNSHIP:

MedStar Union Memorial Hospital, Baltimore, Maryland, Surgical Intern July 1973 to June 1974

RESIDENCIES:

Tien Medical Center, Taipei, Taiwan, First Year Resident of Medicine (1972-1973)

MedStar Union Memorial Hospital, Resident in Surgery (1974-1975)

Johns Hopkins Hospital, Orthopedic Resident (1975)

MedStar Union Memorial Hospital, Assistant Resident in Orthopedic Surgery (1976)

MedStar Union Memorial Hospital, Chief of Residents in Hand and Orthopedic Surgery (1977-1978)

FELLOWSHIPS:

Johns Hopkins University School of Medicine, Clinical Fellowship in Orthopedic Surgery (1975-1978)

Dr. Shih-Ann Chen

Superintendent, Taichung Veterans General Hospital

Taichung Veterans General Hospital, a 1,624-bed hospital, is located in central Taiwan. It started medical services on 1982. Since 1991 it has been accredited "Medical Center and First-Class Teaching Hospital" by National Health Bureau. It provides safe, high-quality medical services. With the vision "To deliver intelligent and holistic medicine," we are devoted to medical AI research to develop a world-renowned Smart Hospital.

Zoe: AI+HI Smart Critical Care System by Taichung Veterans General Hospital, Tunghai University, and Advantech Co., Ltd co-create an aim to tackle the rapidly evolving and complex nature of critical care medicine and the challenges of shortage in critical care medical personnel. We centered on the main themes of critical care medicine: respiratory care, bacteremia, end-of-life care, acute kidney injury, and pain & sedation. Using international coding systems, we built the 6-year critical care database with 66.1 million records across 24 categories and 339 features. More than ten artificial intelligence (AI) models have been developed to assist clinical care deci sion-making. We anticipate the clinically effective implementation of smart medical healthcare and positive benefits to more excellent human health and welfare.

AI techniques have been applied in cardiovascular medicine by Taichung and Taipei Veterans General Hospital,to explore novel genotypes and phenotypes, improve the quality of patient care, enable cost-effectiveness, and reduce readmission and mortality rates. In Taiwan, under the cooperation of industry and academia, several AI algorithms have been developed, including the ECG AI, cardiovascular imaging, and interventional cardiology platforms. AI will soon lead to a paradigm shift toward personalized precision cardiovascular medicine. Further, the increasing use of AI prediction models will aid in deciding tailored therapies with predictive characteristics.

Speaker Introduction

Shih-Ann Chen, MD, is Professor of Medicine at National Yang Ming Chiao Tung University School of Medicine, Superintendent in Taichung Veterans General Hospital, Taichung, Taiwan, also Adjunct Professor at Case Western Reserve University, Ohio, USA.

In his more than 30-year period of work in arrhythmology, Prof. Chen and his group members are devoted to investigate the mechanisms and ablation techniques for different types of cardiac arrhythmias, and published more than 769 original articles, more than 215 reviews, editorials, and textbook chapters, including more than 70 articles in top ranking cardiology journals, nature reviews cardiology, and annals of internal medicine. Further, he and Prof. Michel Haissaguerre are the first two pioneers in the world to develop the atrial fibrillation ablation technique. Prof Chen is the first person in the world to edit the textbook of "Thoracic Vein Arrhythmia", which pro vides the novel concept of atrial fibrillation in the era of interventional cardiac electrophysiology.

In 2007, 2011 and 2016, he was appointed as the chairman of the writing group for the chapter of atrial fibrillation mechanism in the consensus document of Atrial Fibrillation Ablation by Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society, the chapter of Pathophysiology of Atrial Fibrillation in the Venice Charter for Atrial Fibrillation Ablation. In 2010 March, he received the Simon Dack Award for Outstanding Scholarship from the American College of Cardiology, USA. Further, he is the founder and the course director of the Asia-Pacific Atrial Fibrillation Symposium since 2005, and International Forum of Ventricular Arrhythmia since 2015, founder and the president of the Asia-Pacific Heart Rhythm Society in 2012 and 2013. Congress president of 2012 and 2018 Asia-Pacific Heart Rhythm Society annual scientific session.

Yu-Bin Huang

Deputy Project Director, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute(ITRI)

Presentation Introduction

The global healthcare systems and industry have undergone tremendous changes. Taiwan has spurred the development of many innovative MedTech solutions to improve the healthcare quality, clinical outcomes, efficiency and human safety. Join hands with global partner, we could together create a better future of healthcare.

Speaker Introduction

With 13+ years of healthcare market research and consulting experience, Yu-Bin has provided advisory services to Government, Taiwan local corporations as well as multinational corporations. In recent years, Yu-Bin has dedicated to facilitate Taiwan MedTech Startups overcoming commercialization hurdles.

AI technologies have improved rapidly over the past decade and have transformed the healthcare industry for improving the quality of physician-patient interaction and human life. This AI-based software for diagnostics, prevention, treatment, or monitoring of disease falls into a category called ‘software as a medical device’ (SaMD) and growing faster than ever before. Taiwan AI Labs built up the medical federated learning framework among several prestigious national medical centers in Taiwan. It laying the foundation world for industry developers form all over the world an environment to build up, validate and practice SaMD solution in real with trusted privacy protection regulation. Collaboration with our high-quality alliance and realized the future healthcare solution quicker than ever.

Speaker Introduction

Ethan Tu is most well-known as the founder of PTT, Taiwan’s largest and most popular online bulletin board system. In the US, he worked at the National Institute of Health (NIH) to develop cancer detection systems and human genetic research. He also worked as Microsoft’s Director of Research and Development for AI in the Asia Pacific Region for 11 years, and was a key figure in development of Microsoft’s Cortana.

In 2017, Ethan founded Taiwan AI Labs, Asia’s first open AI research organization specializing in next generation AI solutions. AI Labs has shown significant results in medical AI/imaging applications, which contributed to the detection of Covid 19 from chest x-rays during the pandemic. He also started The Taiwan AI Federated Learning Alliance to encourage the pooling of data samples for better AI advancement while protecting privacy rights. Ethan also leads teams to develop AI solutions for drones, Smart Cities, speech and facial recognition, and the fighting of fake news.

Building people-oriented AI technologies for everyday life has been Ethan’s biggest faith and focus, which explains AI Labs’ mission: “Innovate AI in Taiwan and for The World, bring technology to meet nature and humanity, and create impacts and improvements for human well-being. “

Ethan also holds many positions in several groups and organizations. Board of directors at Chunghwa Telecom Board of directors at Taiwan Creative Content Agency (TAICCA) Consultant at Asia Silicon Valley Development Agency (ASVDA) Consultant at Digital Nation & Innovative Economic Development Program (DIGI+)

Ethan Tu holds a bachelor’s degree and master’s degree in computer science from National Taiwan University (NTU).

Dr. Jim Long

CEO and Co-founder of AESOP Technology

AESOP, which stands for AI-Enhanced Safety of Prescription, is working to make physician data entry easier, faster, and less error-prone. AESOP was founded in 2020. They aims to optimize the clinical decision support process with more flexible AI-powered technology to improve patient safety and medical coding quality.

Jim Long, a former CIO in the medical center and CTO in the manufacturing industry, has more than 25 years of experience driving healthcare and electronic organizational growth, operational effectiveness, and optimal use of emerging technologies.

Dr. Bruce Yu

Founder and CEO of BROADSIMS Inc.

Presentation Introduction

No need to install APP in tablet or mobile to control discrete peripheral sensors.

Variant vital-signs can be captured by installing APP in a single device 5G-VSP.

In-Hospital: ICU, RCW, Anesthesia Department, Post-Anesthesia, Recovery Room, Ward, ER, Ambulatory, Dialysis Room

Off-Hospital: Telehealth, home care

Speaker Introduction

Dr. Bruce Yu is a serial entrepreneur with multiple academic discipline background, including electronics, communications, and biomedical engineering. Currently, he is the Founder/CEO of BROADSIMS Inc.

BROADSIMS is the first providing an APP-Installable 5G vital-sign solution as an open-innovation platform (5G-VSP), including ECG, SpO2, and NIBP functions for clinical research and care providers. Extra features, including portable ultrasound, EEG, stethoscope, blood glucose, weight, are also combined into this 5G-VSP. With open-raw data strategy, hospitals and clinical researchers can easily utilize the raw data to develop respective innovative and AI applications. All measurement history is available any time, creating a smart medical ecosystem.

AI prediction and analysis are achievable, when raw data and images are available.

Joni Cheng

Consultant of Quality & Regulatory Affairs V5 Technologies

Presentation Introduction

V5 Technologies is the world’s leading AI image analysis solutions provider, offering superior products backed by image algorithms and deep learning technologies.

Our pulmonary application, the V5 Lung-CT can identify and highlight small pulmonary nodules accurately and effectively assist doctors in finding and diagnosing nodules, with essential information. With sensitivity as high as 98.4%, the V5 Lung-CT system is designed to assist doctors in the early-stage detection of pulmonary nodules in asymptomatic populations. In 2021, V5 Technologies received the R&D accomplishment Award from Hsinchu Science Park, and Our Lung-CT system won the coveted Innovative Product Award. This year, V5 received the Taipei Bio Tech Award2022, Interdisciplinary Excellence Special Mention Award from Taipei City Government.

V5 Technologies is at the vanguard of AI analysis and detection technology. We hope we can develop and deliver more experience in more area, from Taiwan to USA, and we look forward to partnering with you.

Speaker Introduction

Joni Cheng is the Senior Manager of V5 TECHNOLOGIES CO., LTD. She is responsible for the quality and Regulatory affairs of medical business, in cybersecurity, privacy, risk, regulatory compliance, and commercialization. She took part in formulating quality system projects and has already obtained certifications from the Taiwan government and international agencies, such as ISO 13485 and QMS system. She holds a Master of Science in Management from The Glasgow University, UK and Professional Master of Law in Business Administration from The National Taiwan University.